Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies

Robert E. Coleman, Jean Jacques Body, Julie R. Gralow, Allan Lipton

Research output: Contribution to journalReview article

45 Citations (Scopus)

Abstract

Hormone-receptor-positive breast cancer in postmenopausal women is treated increasingly with aromatase inhibitors because of increased efficacy and reduced incidence of endometrial cancer compared with tamoxifen. However, aromatase inhibitor therapy increases bone turnover as a result of nearly complete oestrogen depletion, leading to increases in bone loss and fragility fractures that erode patients' functional independence and quality of life. Management of patients with aromatase inhibitor-associated bone loss (AIBL) is currently evolving and intervention strategies are under investigation. Although no treatments are specifically approved for AIBL, bisphosphonates are currently the intervention of choice for patients with low bone mineral density or evidence of rapid bone turnover, along with adequate calcium and vitamin D supplementation and a healthy lifestyle. In this setting, the majority of information available regarding bisphosphonate efficacy is from studies of intravenous zoledronic acid (4 mg) every 6 months. Data from four large international studies (three of identical design in postmenopausal women and one in premenopausal women) indicate that zoledronic acid is effective in the management of AIBL. Treatment algorithms based on risk factors and bone mineral density are under development, and the results of ongoing studies should help define optimal bone health management for patients undergoing aromatase inhibitor treatment for early breast cancer.

Original languageEnglish (US)
JournalCancer Treatment Reviews
Volume34
Issue numberSUPPL. 1
DOIs
StatePublished - Jan 1 2008

Fingerprint

Aromatase Inhibitors
zoledronic acid
Breast Neoplasms
Bone and Bones
Bone Remodeling
Diphosphonates
Bone Density
Therapeutics
Tamoxifen
Endometrial Neoplasms
Vitamin D
Estrogens
Quality of Life
Hormones
Calcium
Incidence
Health

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Coleman, Robert E. ; Body, Jean Jacques ; Gralow, Julie R. ; Lipton, Allan. / Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies. In: Cancer Treatment Reviews. 2008 ; Vol. 34, No. SUPPL. 1.
@article{c9b1cd4c43ac49d1895c12894e14ece6,
title = "Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies",
abstract = "Hormone-receptor-positive breast cancer in postmenopausal women is treated increasingly with aromatase inhibitors because of increased efficacy and reduced incidence of endometrial cancer compared with tamoxifen. However, aromatase inhibitor therapy increases bone turnover as a result of nearly complete oestrogen depletion, leading to increases in bone loss and fragility fractures that erode patients' functional independence and quality of life. Management of patients with aromatase inhibitor-associated bone loss (AIBL) is currently evolving and intervention strategies are under investigation. Although no treatments are specifically approved for AIBL, bisphosphonates are currently the intervention of choice for patients with low bone mineral density or evidence of rapid bone turnover, along with adequate calcium and vitamin D supplementation and a healthy lifestyle. In this setting, the majority of information available regarding bisphosphonate efficacy is from studies of intravenous zoledronic acid (4 mg) every 6 months. Data from four large international studies (three of identical design in postmenopausal women and one in premenopausal women) indicate that zoledronic acid is effective in the management of AIBL. Treatment algorithms based on risk factors and bone mineral density are under development, and the results of ongoing studies should help define optimal bone health management for patients undergoing aromatase inhibitor treatment for early breast cancer.",
author = "Coleman, {Robert E.} and Body, {Jean Jacques} and Gralow, {Julie R.} and Allan Lipton",
year = "2008",
month = "1",
day = "1",
doi = "10.1016/j.ctrv.2008.03.005",
language = "English (US)",
volume = "34",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "SUPPL. 1",

}

Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies. / Coleman, Robert E.; Body, Jean Jacques; Gralow, Julie R.; Lipton, Allan.

In: Cancer Treatment Reviews, Vol. 34, No. SUPPL. 1, 01.01.2008.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies

AU - Coleman, Robert E.

AU - Body, Jean Jacques

AU - Gralow, Julie R.

AU - Lipton, Allan

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Hormone-receptor-positive breast cancer in postmenopausal women is treated increasingly with aromatase inhibitors because of increased efficacy and reduced incidence of endometrial cancer compared with tamoxifen. However, aromatase inhibitor therapy increases bone turnover as a result of nearly complete oestrogen depletion, leading to increases in bone loss and fragility fractures that erode patients' functional independence and quality of life. Management of patients with aromatase inhibitor-associated bone loss (AIBL) is currently evolving and intervention strategies are under investigation. Although no treatments are specifically approved for AIBL, bisphosphonates are currently the intervention of choice for patients with low bone mineral density or evidence of rapid bone turnover, along with adequate calcium and vitamin D supplementation and a healthy lifestyle. In this setting, the majority of information available regarding bisphosphonate efficacy is from studies of intravenous zoledronic acid (4 mg) every 6 months. Data from four large international studies (three of identical design in postmenopausal women and one in premenopausal women) indicate that zoledronic acid is effective in the management of AIBL. Treatment algorithms based on risk factors and bone mineral density are under development, and the results of ongoing studies should help define optimal bone health management for patients undergoing aromatase inhibitor treatment for early breast cancer.

AB - Hormone-receptor-positive breast cancer in postmenopausal women is treated increasingly with aromatase inhibitors because of increased efficacy and reduced incidence of endometrial cancer compared with tamoxifen. However, aromatase inhibitor therapy increases bone turnover as a result of nearly complete oestrogen depletion, leading to increases in bone loss and fragility fractures that erode patients' functional independence and quality of life. Management of patients with aromatase inhibitor-associated bone loss (AIBL) is currently evolving and intervention strategies are under investigation. Although no treatments are specifically approved for AIBL, bisphosphonates are currently the intervention of choice for patients with low bone mineral density or evidence of rapid bone turnover, along with adequate calcium and vitamin D supplementation and a healthy lifestyle. In this setting, the majority of information available regarding bisphosphonate efficacy is from studies of intravenous zoledronic acid (4 mg) every 6 months. Data from four large international studies (three of identical design in postmenopausal women and one in premenopausal women) indicate that zoledronic acid is effective in the management of AIBL. Treatment algorithms based on risk factors and bone mineral density are under development, and the results of ongoing studies should help define optimal bone health management for patients undergoing aromatase inhibitor treatment for early breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=44649083063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44649083063&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2008.03.005

DO - 10.1016/j.ctrv.2008.03.005

M3 - Review article

C2 - 18486346

AN - SCOPUS:44649083063

VL - 34

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - SUPPL. 1

ER -